1. Description
1. Chemical Properties: A synthetic linear active short peptide with precisely engineered amino acid sequence. Its core targets are neuroprotective receptors on neuronal cell surfaces and neurotrophic factor-related signaling pathways. It specifically binds to target cells in damaged neural tissue without non-specific binding to normal tissue cells. Chemically stable, it maintains high activity for over 48 hours in human body fluids at pH (7.2-7.4). Its resistance to enzymatic degradation by antibodies surpasses that of unmodified peptides. It exhibits no contraindications for combination with commonly used clinical neurotrophic agents or anti-inflammatory drugs. Designed with a low molecular weight range (300-800 Da), it rapidly crosses the blood-brain barrier post-injection to exert effects, compatible with intravenous, intramuscular, and intrathecal administration.
2. Physical Properties: The pharmaceutical-grade finished product is a freeze-dried sterile powder, appearing as white to off-white loose crystals. It is odorless and free of foreign matter. It exhibits excellent water solubility (solubility ≥80 mg/mL) and rapidly dissolves in commonly used clinical injection solvents such as sterile water for injection, saline, and 5% glucose injection. Upon dissolution, it forms a colorless, transparent, and clear liquid free of precipitation or turbidity. Store at -20°C in vacuum-sealed containers protected from light. Avoid repeated freeze-thaw cycles. The medicinal-grade lyophilized powder has a shelf life of 2 years. Once dissolved, use immediately. Any unused product must be stored in a sterile environment at 4°C for no longer than 24 hours.
3. Source and Preparation: No natural extraction source exists. The entire process employs precise pharmaceutical-grade solid-phase peptide synthesis. Using high-purity pharmaceutical-grade L-type amino acids as raw materials, it undergoes condensation, deprotection, and peptide chain assembly. Following multiple HPLC purifications, it is freeze-dried and sterilized to produce the injectable powder. The entire production process complies with GMP pharmaceutical manufacturing standards. Product purity ≥99% (HPLC detection), endotoxin content ≤0.01 EU/mg, with no residual heavy metals, bacteria, pyrogens, or synthetic byproducts. Passes triple testing for sterility, safety, and activity stability, directly meeting raw material requirements for injectable formulations.
2. Application
1. Core Clinical Applications in Neurology
Acute Neurological Injury Intervention: Used as an adjunctive treatment for acute neurological injuries including the acute phase of stroke (cerebral infarction, cerebral hemorrhage), traumatic brain injury, spinal cord injury, and peripheral nerve transection/contusion. Administered via injection for rapid action on damaged neural tissue, laying the foundation for neural repair following emergency care. Suitable for clinical use in neurology and emergency departments across all hospital levels.
Supportive Therapy for Neurodegenerative Diseases: Used for early-to-mid stage supportive intervention in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as clinical management of age-related cognitive decline. Serves as a synergistic ingredient in neurotrophic agents to alleviate functional deterioration caused by progressive neuronal damage.
Treatment of Peripheral Neuropathy: Used for chronic peripheral neuropathies including diabetic peripheral neuropathy, chemotherapy-induced peripheral nerve damage, and alcoholic peripheral neuritis. It improves symptoms such as limb numbness, tingling, and sensory loss.
2. Applications in Rehabilitation Medicine
Post-surgical Neural Rehabilitation: Used for neural function recovery following brain tumor resection, spinal cord tumor removal, peripheral nerve anastomosis, and similar procedures. When combined with physical therapy, it accelerates regeneration and functional restoration of damaged nerves, reduces postoperative neurological dysfunction incidence, and complements rehabilitation protocols in physical medicine, orthopedics, and neurosurgery.
Repair of Sports-Related Nerve Injuries: Used for rehabilitation of acute sports-related nerve injuries (e.g., sciatic nerve or brachial plexus contusions) in professional athletes and high-intensity exercisers. Administered via intramuscular injection to rapidly alleviate limb movement impairment and pain caused by nerve damage, shortening the rehabilitation period.
3. Applications in Neuroscience Research
As a specialized neuroprotective peptide tool, it is used in experimental studies involving in vitro neuronal injury models and animal neurotrauma models. It analyzes regulatory mechanisms affecting neuronal apoptosis and neurotrophic factor expression, providing experimental evidence for novel neuroprotective drug development.
It is employed in modeling and intervention studies of animal models for neurodegenerative diseases to explore the therapeutic effects of peptide formulations on neurodegenerative lesions, providing data support for optimizing clinical treatment protocols.
3. Main Efficacy
Core Efficacy: Targets neuroprotection and inhibits neuronal apoptosis
Mechanism: Specifically binds to anti-apoptotic receptors on damaged neurons, activates downstream anti-apoptotic signaling pathways such as PI3K/Akt and ERK, inhibits the expression and activation of pro-apoptotic proteins (Caspase-3, Bax), thereby blocking programmed neuronal apoptosis induced by ischemia, hypoxia, trauma, oxidative stress, and other factors. This reduces neuronal cell death in damaged areas, maintains the structural integrity of neural tissue, and creates conditions for subsequent neural repair. Following injection, it rapidly forms a high-concentration active zone locally within damaged neural tissue, demonstrating significantly superior targeting compared to orally administered neuroprotective agents.
Key Effects: Promotes neural tissue repair and functional reconstruction
Mechanism: Regulates glial cell activity to enhance synthesis and release of endogenous neurotrophic factors (BDNF, NGF), stimulating axonal and dendritic regeneration in damaged neurons. Concurrently promotes Schwann cell (peripheral nerves) and astrocyte proliferation and differentiation (central nervous system), facilitating myelin sheath repair and regeneration. This accelerates the restoration of damaged nerve signal conduction, improving symptoms such as limb motor impairment, cognitive dysfunction, and sensory abnormalities caused by nerve injury. Clinical data indicates that when combined with standardized treatment, it can enhance post-nerve injury functional recovery efficiency by over 30%.
Synergistic Effects: Anti-inflammatory and Antioxidant, Alleviating Secondary Neurotissue Damage
Mechanism: Inhibits the release of local pro-inflammatory factors (TNF-α, IL-1β, IL-6) in damaged neurotissue, reducing aseptic inflammatory responses and preventing secondary neurotissue damage caused by excessive cytokine release; Simultaneously, it scavenges reactive oxygen species (ROS) within neurons, reducing oxidative stress damage to neuronal membranes, mitochondria, and DNA. This maintains neuronal energy metabolism, alleviates neuronal fatigue and injury, and synergizes with anti-apoptotic and pro-regenerative effects to achieve comprehensive “protection-anti-inflammation-repair” intervention throughout the nerve injury process.
Safety Profile: Low toxicity and minimal side effects with excellent clinical tolerability
As a synthetic short-chain peptide formulation, it exhibits high biocompatibility with human physiology and lacks immunogenicity, causing no allergic or rejection reactions post-injection. Clinical toxicology studies confirm no significant hepatotoxicity, nephrotoxicity, or cardiovascular toxicity within standard clinical dosage ranges. Only a small number of individuals may experience transient, mild injection-site redness or soreness, which resolves spontaneously without special treatment. No long-term adverse effects are observed, making it suitable for prolonged, phased clinical injection administration.
